Wednesday 10, Mar 2010
Protein known to suppress androgen receptors may be useful for treating prostate cancer
According to a finding reported in Proceedings of the National Academy of Sciences Online Early Edition, a protein known for regulating androgen receptor expression may be the focal point to stage and treat testosterone-fueled prostate cancer.
This finding was reported by researchers from the College of Georgia.
Dr. Yehia Daaka, Distinguished Chair in Oncologic Pathology in the MCG School of Medicine and co-author of the study, said that an increase in the number of androgen receptors is considered to be behind the progression of prostate cancer in men with advanced disease.
Collaborators on this study included Dr. Vijayabaskar Lakshmikanthan, postdoctoral fellow; Dr. Lin Zou, former postdoctoral fellow;Â Jae Kim, graduate student; Dr. Nidia C. Messias, assistant professor; and Dr. Zhongzhen Nie, assistant professor; from the MCG Department of Pathology; and Drs. Allison Michal, and Jeffrey L. Benovic from Thomas Jefferson University.
Tags: βarrestin2, prostate cancer, steroids, testosterone
Posted in Steroid Cycles, steroid nation, Steroids and Anabolic Steroids